Market Trends of Global Postmenopausal Osteoporosis Industry
This section covers the major market trends shaping the Postmenopausal Osteoporosis Market according to our research experts:
The Bisphosphonates Segment is Expected to Hold Largest Share in the Postmenopausal Osteoporosis Market Over Forecast Period
The bisphosphonates class of drug is expected to be accounted for the market's maximum share, which can be attributed to their ability to prevent the loss of bone density and thereby minimize the fracture risk by 50%. Additionally, bisphosphonates can be tolerated by most patients on a long-term basis. For instance, according to an article published in April 2021, titled 'Bisphosphonate Medications for Osteoporosis: Concerns Regarding Risks and Side Effects', by inhibiting osteoclast activity, bisphosphonates reduce bone resorption and numerous studies have demonstrated that this family of drugs can increase bone density and lower fracture risk in those with low bone density. Hence, they are prescribed widely for most patients with osteoporosis and thus expected to have a significant share in the studied market.
Alendronate, risedronate, ibandronate, and zoledronic acid are some of the most prescribed bisphosphonates to prevent and treat postmenopausal osteoporosis. A new regimen through the intravenous route is under investigation, and positive results from the trial can further accelerate the market of bisphosphonates during the forecast period. Bisphosphonates are generally prescribed for five years, and the bone-protective benefit of the drug continues even after the treatment discontinuation. Therefore, owing to the above-mentioned factors, the bisphosphate segment is expected to have a significant market share in the postmenopausal osteoporosis market.
North America Region is Expected to Occupy a Significant Share in the Postmenopausal Osteoporosis Market
North America contributes the highest revenue in the market due to its developed healthcare infrastructure, presence of major industry players, high diagnosis and treatment rate, more patient compliance, and large patient base. The United States contributes the maximum share in North America. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2021, about 18.8% of women aged 50 years or more had osteoporosis. The prevalence is expected to increase further due to sedentary lifestyles and unhealthy eating & drinking habits. According to the National Osteoporosis Foundation, it is projected that by 2030, about 71 million Americans will have osteoporosis and low bone mass condition.
High research and development activities due to investment by market players and research institutes are expected to further accelerate the market growth during the forecast period from 2022 to 2027. According to data published on clinicaltrial.gov as of June 2021, about 25 active Phase III and Phase IV clinical trials are going on in the United States for osteoporosis drugs. Also, as per the May 2022 update of the National Institute of Health of the United States, about USD 155 million in funding is allocated for osteoporosis in 2021, an increase of USD 7 million from the previous years, and this funding are further expected to have a positive impact on the studied market. Therefore, due to the above-mentioned factors, the postmenopausal osteoporosis market is expected to grow in the North American region over the forecast period.
